Carcinotech, an Edinburgh, Scotland, UK-based 3D printed micro-tumour manufacturer, raised £4.2M in funding.
The round was led by Eos Advisory, alongside the Investment Fund for Scotland (IFS) managed by Maven Capital Partners, Scottish Enterprise, Old College Capital, Investing Women Angels, and existing investors TRICAPITAL, SIS Ventures, Gabriel Investment Syndicate, and Alba Equity.
The company intends to use the funds to expand operations and its R&D efforts.
Led by Ishani Malhotra, CEO and Founder, Carcinotech provides Carcino3D, a product with technology that enable the manufacture of 3D printed micro-tumours using cells derived from patient biopsies and blood samples to precisely simulate the tumour microenvironment thereby accelerating ethical drug screening and the delivery of more effective cancer treatments to market.
Commenting on the news, Ishani Malhotra said: “Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development.”
FinSMEs
29/01/2024